Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Review

The Innate Immune System and Its Role in Allergic Disorders

Vandenbulcke L. · Bachert C. · van Cauwenberge P. · Claeys S.

Author affiliations

Upper Airways Research Laboratory, Department of Otorhinolaryngology, Ghent University, Ghent, Belgium

Related Articles for ""

Int Arch Allergy Immunol 2006;139:159–165

Do you have an account?

Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information











I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Review

Received: November 03, 2005
Published online: February 01, 2006
Issue release date: January 2006

Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 0

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: https://www.karger.com/IAA

Abstract

Background: There has been an increasing prevalence of allergic diseases in the Western world over the last decades. The hygiene hypothesis has been proposed as a possible explanation for this epidemical trend in allergy. A key role in this theory is assigned to the reduced microbial stimulation of the Toll-like receptors (TLRs) in early life, which could lead to a weaker Th1 response and a stronger Th2 response to allergens. The individual immunological response is determined by the interplay between the dose and timing of exposure to endotoxins, other environmental factors and genetic predisposition. In the development and progression of allergic disorders, the innate immune system plays an important role. Objective: In this review, we discuss the paradoxical effects that may appear when the innate immune components are triggered. We review the influence of changes in the gene sequence and TLR expression in relation to the overall pattern of commensals and pathogens. We explored the possibility of alternative stimulations of the immune system by CpG oligodeoxynucleotides and probiotics as therapeutic devices against this endemic disease in Western society. Methods: Selection of papers was based on the importance of their contribution to the understanding of innate immunity and its implications. Results and Conclusion: The innate immune system plays an important role in both the protection against and the enhancement of allergic disorders, but the mechanisms are still unclear. Nevertheless, gene polymorphisms and triggers of the innate immune system provide therapeutic targets for protection against and treatment of allergic disorders.

© 2006 S. Karger AG, Basel


References

  1. Check W: Innate immunity depends on Toll-like receptors. ASM News 2004;70:317–322.
    External Resources
  2. Basset C, Holton J, O’Mahony R, Roitt I: Innate immunity and pathogen-host interaction. Vaccine 2003;21(suppl 2):S12–S23.
    External Resources
  3. Abreu MT, Arditi M: Innate immunity and Toll-like receptors: clinical implications of basic science research. J Pediatr 2004;144:421–429.
  4. Beutler B: Toll-like receptors: how they work and what they do. Curr Opin Hematol 2002;9:2–10.
  5. Boman HG: Antibacterial peptides: basic facts and emerging concepts. J Intern Med 2003;254:197–215.
  6. Kim DS, Drake-Lee AB: Infection, allergy and the hygiene hypothesis: historical perspective. J Laryngol Otol 2003;117:946–950.
  7. Strachan DP: Hay fever, hygiene, and household size. BMJ 1989;299:1259–1260.
  8. Romagnani S: The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both? Immunology 2004;12:352–363.
  9. Wills-Karp M, Santeliz J, Karp CL: The germless theory of allergic disease: revisiting the hygiene hypothesis. Nat Rev Immunol 2001;1:69–75.
  10. Kidd P: Th1/Th2 Balance: The hypothesis, its limitations, and implications for health and disease. Altern Med Rev 2003;8:223–246.
    External Resources
  11. Eder W, Klimecki W, Yu L, von Mutius E, Riedler J, Braun-Fahrländer C, Nowak D, Martinez FD, and the ALEX Study Team: Toll-like receptor 2 as a major gene for asthma in children of European farmers. J Allergy Clin Immunol 2004;113:482–488.
  12. Beutler B: Innate immunity: an overview. Mol Immunol 2004;40:845–859.
  13. Martinez FD: The coming-of-age of the hygiene hypothesis. Respir Res 2001;2:129–132.
  14. von Mutius E, Braun-Fahrländer C, Schierl R, Riedler J, Ehlermann S, Maisch S, Waser M, Nowak D: Exposure to endotoxin or other bacterial components might protect against the development of atopy. Clin Exp Allergy 2000;30:1230–1234.
  15. Lauener RP, Birchler T, Adamski J, Braun-Fahrländer C, Bufe A, Herz U, von Mutius E, Nowak D, Riedler J, Waser M, Sennhauser FH, and the ALEX study group: Expression of CD14 and Toll-like receptor 2 in farmers’ and non-farmers’ children. Lancet 2002;360:465–466.
  16. Riedler J, Braun-Fahrländer C, Eder W, Schreuer M, Waser M, Maisch S, Carr D, Schierl R, Nowak D, von Mutius E, and the ALEX Study Team: Exposure to farming in early life and development of asthma and allergy: a cross-sectional survey. Lancet 2001;358:1129–1133.
  17. Diamond G, Legarda D, Ryan LK: The innate immune response of the respiratory epithelium. Immunol Rev 2000;173:27–38.
  18. Velasco G, Campo M, Manrique OJ, Bellou A, He H, Arestides RS, Schaub B, Perkins DL, Finn PW: Toll-like receptor 4 or 2 agonists decrease allergic inflammation. Am J Respir Cell Mol Biol 2005;32:218–224.
  19. Gereda JE, Leung DY, Thatayatikom A, Streib JE, Price MR, Klinnert MD, Liu AH: Relation between house-dust endotoxin exposure, type 1 T-cell development, and allergen sensitisation in infants at high risk of asthma. Lancet 2000;355:1680–1683.
  20. Liu AH: Endotoxin exposure in allergy and asthma: reconciling a paradox. J Allergy Clin Immunol 2002;109:379–392.
  21. Becker MN, Diamond G, Verghese MW, Randell SH: CD14-dependent lipopolysaccharide-induced beta-defensin-2 expression in human tracheobronchial epithelium. J Biol Chem 2000;275:29731–29736.
  22. Stampfli MR, Cwiartka M, Gajewska BU, Alvarez D, Ritz SA, Inman MD, Xing Z, Jordana M: Interleukin-10 gene transfer to the airway regulates allergic mucosa sensitization in mice. Am J Respir Cell Mol Biol 1999;21:586–596.
  23. Wysocka M, Robertson S, Riemann H, Caamano J, Hunter C, Mackiewicz A, Montaner LJ, Trinchieri G, Karp CL: IL-12 suppression during experimental endotoxin tolerance: dendritic cell loss and macrophage hyporesponsiveness. J Immunol 2001;166:7504–7513.
  24. Trinchieri G: Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol 1998;70:83–243.
  25. Braun-Fahrländer C, Riedler J, Herz U, Eder W, Waser M, Grize L, Maisch S, Carr D, Gerlach F, Bufe A, Lauener RP, Schierl R, Renz H, Nowak D, von Mutius E, for the Allergy and Endotoxin Study Team: Environmental exposure to endotoxin and its relation to asthma in school-age children. N Engl J Med 2002;347:869–877.
  26. Weiss ST: Eat dirt. The hygiene hypothesis and allergic diseases. N Engl J Med 2002;347:930–931.
  27. van Schayck CP, Knottnerus JA: Can the ‘hygiene hypothesis’ be explained by confounding by behaviour? J Clin Epidemiol 2004;57:435–437.
  28. Eisenbarth SC, Piggott DA, Huleatt JW, Visintin I, Herrick CA, Bottomly K: Lipopolysaccharide-enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen. J Exp Med 2002;196:1645–1651.
  29. Lawton JA, Ghosh P: Novel therapeutic strategies based on toll-like receptor signaling. Curr Opin Chem Biol 2003;7:446–451.
  30. Rizzo MC, Naspitz CK, Fernandez-Caldas E, Lockey RF, Mimica I, Sole D: Endotoxin exposure and symptoms in asthmatic children. Pediatr Allergy Immunol 1997;8:121–126.
  31. Michel O, Ginanni R, Duchateau J, Vertongen F, Le Bon B, Sergysels R: Domestic endotoxin exposure and clinical severity of asthma. Clin Exp Allergy 1991;21:441–448.
  32. Michel O, Kips J, Duchateau J, Vertongen F, Robert L, Collet H, Pauwels R, Sergysels R: Severity of asthma is related to endotoxin in house dust. Am J Respir Crit Care Med 1996;154(6 pt 1):1641–1646.
  33. Park JH, Gold DR, Spiegelman DL, Burge HA, Milton DK: House dust endotoxin and wheeze in the first year of life. Am J Respir Crit Care Med 2001;163:322–328.
  34. Tulic MK, Wale JL, Holt PG, Sly PD: Modification of the inflammatory response to allergen challenge after exposure to bacterial lipopolysaccharide. Am J Respir Cell Mol Biol 2000;22:604–612.
  35. Reed CE, Milton DK: Endotoxin-stimulated innate immunity: A contributing factor for asthma. J Allergy Clin Immunol 2001;108:157–166.
  36. Lauw FN, ten Hove T, Dekkers PE, de Jonge E, van Deventer SJ, van der Poll T: Reduced Th1, but not Th2, cytokine production by lymphocytes after in vivo exposure of healthy subjects to endotoxin. Infect Immun 2000;68:1014–1018.
  37. Kamochi M, Kamochi F, Kim YB, Sawh S, Sanders JM, Sarembock I, Green S, Young JS, Ley K, Fu SM, Rose CE Jr: P-selectin and ICAM-1 mediate endotoxin-induced neutrophil recruitment and injury to the lung and liver. Am J Physiol 1999;277(2 pt 1):L310–L319.
  38. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, Frees K, Watt JL, Schwartz DA: TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000;25:187–191.
  39. Fageras Bottcher M, Hmani-Aifa M, Lindstrom A, Jenmalm MC, Mai XM, Nilsson L, Zdolsek HA, Bjorksten B, Soderkvist P, Vaarala O: A TLR4 polymorphism is associated with asthma and reduced lipopolysaccharide-induced interleukin-12(p70) responses in Swedish children. J Allergy Clin Immunol 2004;114:561–567.
  40. Schwartz DA: Inhaled endotoxin, a risk for airway disease in some people. Respir Physiol 2001;128:47–55.
  41. Koppelman GH, Reijmerink NE, Colin Stine O, Howard TD, Whittaker PA, Meyers DA, Postma DS, Bleecker ER: Association of a promotor polymorphism of the CD14 gene and atopy. Am J Respir Crit Care Med 2001;163:965–969.
  42. Baldini M, Lohman IC, Halonen M, Erickson RP, Holt PG, Martinez FD: A polymorphism in the 5′-flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol 1999;20:976–983.
  43. Heinzmann A, Dietrich H, Jerkic SP, Kurz T, Deichmann KA: Promotor polymorphisms of the CD14 gene are not associated with bronchial asthma in Caucasian children. Eur J Immunogenet 2003;30:345–348.
  44. Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E: Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001;357:1076–1079.
  45. Isolauri E, Salminen S, Ouwehand AC: Microbial-gut interactions in health and disease. Probiotics. Best Pract Res Clin Gastroenterol 2004;18:299–313.
  46. Cario E, Rosenberg IM, Brandwein SL, Beck PL, Reinecker HC, Podolsky DK: Lipopolysaccaride activates distinct signaling pathways in intestinal epithelial cell lines expressing toll-like receptors. J Immunol 2000;164:966–972.
  47. Fusunyan RD, Nanthakumar NN, Baldeon ME, Walker WA: Evidence for an innate immune response in the immature human intestine: toll-like receptors on fetal enterocytes. Pediatr Res 2001;49:589–593.
  48. Matricardi PM, Rosmini F, Riondino S, Fortini M, Ferrigno L, Rapicetta M, Bonini S: Exposure to foodborne and orofecal microbes versus airborne viruses in relation to atopy and allergic asthma: epidemiological study. BMJ 2000;320:412–417.
  49. Cario E, Podolsky DK: Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000;68:7010–7017.
  50. Strannegard O, Strannegard IL: The causes of the increasing prevalence of allergy: is atopy a microbial deprivation disorder? Allergy 2001;56:91–102.
  51. Kalliomaki M, Kirjavainen P, Eerola E, Kero P, Salminen S, Isolauri E: Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. J Allergy Clin Immunol 2001;107:129–134.
  52. Fuller R: Probiotics in man and animals. J Appl Bacteriol 1989;66:365–378.
  53. Matricardi PM: Probiotics against allergy: data, doubts, and perspectives. Allergy 2002;57:185–187.
  54. Fooks LJ, Fuller R, Gibson GR: Prebiotics, probiotics and human gut microbiology. Int Dairy J 1999;9:53–61.
    External Resources
  55. Isolauri E, Arvola T, Sutas Y, Moilanen E, Salminen S: Probiotics in the management of atopic eczema. Clin Exp Allergy 2000;30:1804–1808.
  56. Majamaa H, Isolauri E: Probiotics: a novel approach in the management of food allergy. J Allergy Clin Immunol 1997;99:179–185.
  57. Rosenfeldt V, Benfeldt E, Nielsen SD, Michaelsen KF, Jeppesen DL, Valerius NH, Paerregaard A: Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J Allergy Clin Immunol 2003;111:389–395.
  58. Rautava S, Kalliomaki M, Isolauri E: Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant. J Allergy Clin Immunol 2002;109:119–121.
  59. Kalliomaki M, Salminen S, Poussa T, Arvilommi H, Isolauri E: Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet 2003;361:1869–1871.
  60. Klinman DM: Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 2004;4:249–258.
  61. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM: CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci 1996;93:2879–2883.
  62. Kline JN, Waldschmidt TJ, Businga TR, Lemish JE, Weinstock JV, Thorne PS, Krieg AM: Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol 1998;160:2555–2559.

Article / Publication Details

First-Page Preview
Abstract of Review

Received: November 03, 2005
Published online: February 01, 2006
Issue release date: January 2006

Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 0

ISSN: 1018-2438 (Print)
eISSN: 1423-0097 (Online)

For additional information: https://www.karger.com/IAA


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.